MED-EL v. Advanced Bionics: Federal Circuit Appeal Voluntarily Dismissed (176 Days)
MED-EL Elektromedizinische Geräte GmbH brought Advanced Bionics to the Federal Circuit over two patents covering MRI-safe disc magnet technology for cochlear implants. After 176 days, the parties jointly agreed to dismiss the appeal under Fed. R. App. P. 42(b), with each side bearing its own costs — leaving the underlying merits unresolved.
Federal Circuit appeal ends by agreement — merits never reached
MED-EL Elektromedizinische Geräte GmbH, an Austrian medical device company and holder of USRE046057E and US8634909B2, appealed to the United States Court of Appeals for the Federal Circuit against Advanced Bionics, a competing cochlear implant manufacturer. The two patents in dispute cover MRI-safe disc magnet configurations for implantable devices and methods for reducing the effect of magnetic and electromagnetic fields on an implant’s internal electronics — technologies that are commercially critical in an era of increasing MRI diagnostic reliance.
The appeal, filed on 4 December 2024, was terminated on 29 May 2025 when both parties jointly agreed to dismiss the proceeding under Federal Rule of Appellate Procedure 42(b). The Federal Circuit ordered each side to bear its own costs. Critically, the dismissal was characterised as ‘voluntary’ in the basis of termination, but the public record does not specify whether the dismissal was with or without prejudice — meaning the scope of any res judicata effect on future claims cannot be confirmed from available docket information alone.
The 176-day resolution is notably swift for a Federal Circuit infringement appeal, suggesting the parties likely reached a private commercial understanding — whether a licensing arrangement, cross-licence, or settlement — before any substantive appellate briefing concluded. What drove the agreement, what financial terms if any were exchanged, and whether MED-EL retains freedom to reassert these patents at the district court level all remain outside the public record. IP professionals monitoring cochlear implant patent enforcement should note that the underlying patents remain presumptively valid and enforceable.
Filing to Voluntary dismissal in 176 days
176 days — resolved faster than many Federal Circuit appeals, which typically run 18–24 months to merits decision
Voluntarily dismissed: what the Federal Circuit order means for both parties
Fed. R. App. P. 42(b) — dismissal by stipulation of parties
Rule 42(b) of the Federal Rules of Appellate Procedure permits parties to jointly move to dismiss an appeal at any time. The Federal Circuit granted that motion here, terminating the appellate proceeding without issuing any ruling on the merits. No appellate panel assessed claim construction, obviousness, or infringement. The order is purely procedural — the court did not endorse either party’s legal position.
Procedural dismissal — no merits rulingThe public record is silent on prejudice status
A voluntary dismissal may be with prejudice (barring refiling of the same claims) or without prejudice (preserving the right to refile). The basis of termination recorded here states only ‘Voluntary dismissal’ — no prejudice designation is publicly visible in the docket. This distinction carries significant legal consequences: if without prejudice, MED-EL could theoretically reassert the same patents; if with prejudice, those appellate claims are extinguished. Counsel should review the underlying stipulation directly.
Prejudice status: not publicly confirmedAppeal withdrawn — patent enforceability preserved in principle
MED-EL as appellant initiated and then agreed to withdraw this Federal Circuit appeal. USRE046057E and US8634909B2 remain issued and presumptively valid — no appellate ruling invalidated or narrowed them. Whether MED-EL secured commercial terms in exchange for the dismissal is unknown. The company retains its patent portfolio and, depending on prejudice status, may retain enforcement options against Advanced Bionics or other cochlear implant competitors.
Patents remain presumptively validAppellate threat removed — underlying exposure unclear
Advanced Bionics exits this Federal Circuit proceeding without an adverse infringement ruling. However, dismissal without a merits decision does not establish non-infringement or invalidity. If the dismissal was without prejudice, Advanced Bionics could face re-litigation on these MRI-safe implant magnet patents at a future date. The absence of fee-shifting suggests neither party was found to have litigated in bad faith at the appellate stage.
No infringement finding either wayFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | MED-EL Elektromedizinische Geräte, GmbH | Company | Austrian cochlear implant manufacturer — holder of USRE046057E and US8634909B2Search in Eureka ↗ |
| Defendant | Advanced Bionics | Individual | Advanced Bionics — US cochlear implant manufacturer and subsidiary of Sonova GroupSearch in Eureka ↗ |
| Plaintiff counsel | Georg Reitboeck | Attorney | Counsel for MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Jonathan Herstoff | Attorney | Counsel for MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Kerry L. Timbers | Attorney | Counsel for MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Lisa M. Tittemore | Attorney | Counsel for MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Sharona Sternberg | Attorney | Counsel for MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Haug Partners LLP | Law Firm | Representing MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Sunstein LLP | Law Firm | Representing MED-EL Elektromedizinische Geräte, GmbHSearch in Eureka ↗ |
| Defendant counsel | Greg Matthew Polins | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Marcus Edward Sernel | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Meredith Zinanni | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Tareq M. Alosh | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant law firm | Kirkland & Ellis, LLP | Law Firm | Representing Advanced BionicsSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order adopts the parties’ stipulation verbatim, ordering dismissal under Fed. R. App. P. 42(b) with each side bearing its own costs. The cost allocation — symmetric, no fee-shifting — suggests neither party had a clearly dominant litigation position at the appellate stage, or that any commercial arrangement between them rendered cost recovery moot. Crucially, the order contains no merits language: no claim construction, no validity ruling, no infringement finding. The patents in suit therefore exit this proceeding with their presumptive validity intact, and Advanced Bionics exits without a judicial non-infringement determination.
USRE046057E & US8634909B2 — MRI-safe cochlear implant magnet technology
USRE046057E is a reissue patent — a category that signals the patent owner sought to correct or broaden claims after initial grant, often in response to competitive developments or prior art discovered post-issuance. It covers MRI-safe disc magnet technology for implantable devices, addressing one of the most clinically significant challenges in cochlear implant design: enabling patients to undergo MRI scans without removing or damaging the implant’s internal magnet. US8634909B2 covers complementary methods for reducing the effect of magnetic and electromagnetic fields on an implant’s internal magnet and electronics — a mechanistically distinct but commercially related claim set.
Together, these two patents represent MED-EL’s IP position in a technology area where regulatory and clinical pressure is intensifying. MRI-conditional labelling has become a meaningful competitive differentiator for cochlear implant manufacturers, as MRI is increasingly the diagnostic standard in neurology, oncology, and cardiology. Any competitor offering an MRI-compatible cochlear implant in the US market must design around — or license — these patents. Advanced Bionics, as a direct market competitor with MRI-compatible product lines, represents exactly the commercial threat profile these patents were designed to address.
Should your team run an FTO against USRE046057E and US8634909B2?
If your organisation is developing, launching, or acquiring any active implantable device with MRI-conditional or MRI-safe specifications — cochlear implants, auditory brainstem implants, bone-anchored hearing systems, or related neurostimulators — USRE046057E and US8634909B2 should be on your FTO checklist. The reissue status of USRE046057E means its claims may be broader than the original grant, and the voluntary dismissal of this appeal means no court has narrowed or invalidated either patent. Both are presumptively valid and enforceable in the US.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of both patents, surface related family members and pending continuations, identify prior art that was or was not considered during prosecution, and flag design-around opportunities in the MRI-safe magnet and shielding space. For R&D teams working on next-generation implant platforms, early FTO analysis against this patent family is materially lower cost than redesign or litigation exposure at commercialisation stage.
Run a freedom-to-operate analysis on USRE046057E to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in cochlear implant & active implant patent disputes
Explore related Federal Circuit infringement appeals involving cochlear implant technology, MRI-safe medical device patents, and active implantable device patent disputes.
What this case signals for the cochlear implant IP landscape
A swift voluntary dismissal at the Federal Circuit in a high-stakes implant patent dispute typically signals private resolution — with significant implications for MRI-safe device freedom to operate.
MRI-safe implant patents remain a live enforcement risk
USRE046057E and US8634909B2 were not invalidated or narrowed by this proceeding. Any company developing cochlear implants, auditory brainstem implants, or other active implantable devices with MRI-conditional ratings should treat these patents as enforceable and conduct FTO analysis before product launch or market expansion.
Rapid Federal Circuit dismissals often signal private licensing terms
A 176-day resolution at the Federal Circuit — without merits briefing completing — is consistent with a negotiated licence or settlement reached in parallel with the appeal. Competitors and investors in the cochlear implant space should consider whether a MED-EL licensing programme covering MRI-safe magnet technology is now active or anticipated.
MED-EL v Advanced — key questions answered
The Federal Circuit appeal in Case No. 25-1249 was voluntarily dismissed by agreement of both parties under Fed. R. App. P. 42(b) on 29 May 2025, 176 days after filing. Each side was ordered to bear its own costs. No merits ruling on infringement or validity of patents USRE046057E or US8634909B2 was issued.
MED-EL asserted two patents: USRE046057E (a reissue patent covering MRI-safe disc magnet technology for implantable devices) and US8634909B2 (covering methods for reducing the effect of magnetic and electromagnetic fields on an implant’s magnet and electronics). Both relate to MRI-compatible cochlear implant design.
No. A dismissal under Fed. R. App. P. 42(b) is purely procedural and contains no merits adjudication. The Federal Circuit issued no ruling on validity, claim construction, or infringement. USRE046057E and US8634909B2 remain presumptively valid and enforceable US patents following this dismissal.
The publicly available docket records the basis of termination as ‘Voluntary dismissal’ without specifying whether it was with or without prejudice. This distinction is legally significant — with prejudice bars refiling; without prejudice preserves it. The underlying stipulation between the parties would contain this information but is not reflected in the public docket data available.
The Federal Circuit ordered each side to bear its own appellate costs, which is consistent with a negotiated resolution where neither party had a clearly dominant position, or where any financial terms agreed privately rendered cost recovery at court level immaterial. This symmetric cost allocation neither confirms nor denies a licensing payment or settlement amount, which remains outside the public record.
PatSnap Eureka searches patents and litigation data to answer instantly.